BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 18353594)

  • 21. Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).
    Sader HS; Flamm RK; Jones RN
    Diagn Microbiol Infect Dis; 2013 May; 76(1):61-8. PubMed ID: 23535208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics.
    Harrison CJ; Woods C; Stout G; Martin B; Selvarangan R
    J Antimicrob Chemother; 2009 Mar; 63(3):511-9. PubMed ID: 19174454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review of the spectrum and potency of orally administered cephalosporins and amoxicillin/clavulanate.
    Sader HS; Jacobs MR; Fritsche TR
    Diagn Microbiol Infect Dis; 2007 Mar; 57(3 Suppl):5S-12S. PubMed ID: 17292577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contemporary evaluation of the in vitro activity and spectrum of cefdinir compared with other orally administered antimicrobials tested against common respiratory tract pathogens (2000-2002).
    Sader HS; Fritsche TR; Mutnick AH; Jones RN
    Diagn Microbiol Infect Dis; 2003 Nov; 47(3):515-25. PubMed ID: 14596971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of the beta-lactam resistance phenotype on the cefuroxime versus cefditoren susceptibility of Streptococcus pneumoniae and Haemophilus influenzae recovered from children with acute otitis media.
    Fenoll A; Aguilar L; Robledo O; Giménez MJ; Tarragó D; Granizo JJ; Gimeno M; Coronel P
    J Antimicrob Chemother; 2007 Aug; 60(2):323-7. PubMed ID: 17562681
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activity of cefditoren against beta-lactamase-positive and -negative Haemophilus influenzae and Moraxella catarrhalis.
    Karlowsky JA; Critchley IA; Draghi DC; Jones ME; Thornsberry C; Sahm DF
    Diagn Microbiol Infect Dis; 2002 Jan; 42(1):53-8. PubMed ID: 11821172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis.
    Bogdanovich T; Clark C; Ednie L; Lin G; Smith K; Shapiro S; Appelbaum PC
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2050-7. PubMed ID: 16723565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative in vitro evaluation of dirithromycin tested against recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae, including effects of medium supplements and test conditions on MIC results.
    Biedenbach DJ; Jones RN; Lewis MT; Croco MA; Barrett MS
    Diagn Microbiol Infect Dis; 1999 Apr; 33(4):275-82. PubMed ID: 10212755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of in vitro activities of tigecycline with other antimicrobial agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in two university hospitals in Istanbul, Turkey.
    Gonullu N; Catal F; Kucukbasmaci O; Ozdemir S; Torun MM; Berkiten R
    Chemotherapy; 2009; 55(3):161-7. PubMed ID: 19390189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-susceptibility trends among Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections in the UK and Ireland, 1999-2007.
    Morrissey I; Maher K; Williams L; Shackcloth J; Felmingham D; Reynolds R;
    J Antimicrob Chemother; 2008 Nov; 62 Suppl 2():ii97-103. PubMed ID: 18819984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resistance patterns of selected respiratory tract pathogens in Poland.
    Skoczyńska A; Kadłubowski M; Waśko I; Fiett J; Hryniewicz W
    Clin Microbiol Infect; 2007 Apr; 13(4):377-83. PubMed ID: 17359321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections.
    Hoban D; Felmingham D
    J Antimicrob Chemother; 2002 Sep; 50 Suppl S1():49-59. PubMed ID: 12239228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Are beta-lactam breakpoints adequate to define non-susceptibility for all Haemophilus influenzae resistance phenotypes from a pharmacodynamic point of view?
    Alou L; Giménez MJ; Sevillano D; Aguilar L; González N; Echeverría O; Torrico M; Coronel P; Prieto J
    J Antimicrob Chemother; 2007 Apr; 59(4):652-7. PubMed ID: 17341471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections.
    Fritsche TR; Kirby JT; Jones RN
    Diagn Microbiol Infect Dis; 2004 Jul; 49(3):201-9. PubMed ID: 15246511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia.
    Biedenbach DJ; Farrell DJ; Flamm RK; Liverman LC; McIntyre G; Jones RN
    Int J Antimicrob Agents; 2012 Apr; 39(4):321-5. PubMed ID: 22306239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species.
    Johnson DM; Biedenbach DJ; Beach ML; Pfaller MA; Jones RN
    Diagn Microbiol Infect Dis; 2000 Jun; 37(2):99-105. PubMed ID: 10863104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment.
    Pfaller MA; Ehrhardt AF; Jones RN
    Am J Med; 2001 Dec; 111 Suppl 9A():4S-12S; discussion 36S-38S. PubMed ID: 11755437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trends in the activity of macrolide and beta-lactam antibiotics and resistance development. Alexander Project Group.
    Schito GC; Mannelli S; Pesce A
    J Chemother; 1997 May; 9 Suppl 3():18-28. PubMed ID: 9248977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
    Jones RN; Sader HS; Stilwell MG; Fritsche TR
    Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibiotic susceptibility of respiratory pathogens recently isolated in Italy: focus on cefditoren.
    Tempera G; Furneri PM; Carlone NA; Cocuzza C; Rigoli R; Musumeci R; Pilloni AP; Prenna M; Tufano MA; Tullio V; Vitali LA; Nicoletti G
    J Chemother; 2010 Jun; 22(3):153-9. PubMed ID: 20566418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.